Preeclampsia diagnostics market

Preeclampsia Diagnostics Market, Test Type (Blood Tests, Urine Analysis, and Others), By Product Type (Instruments and Consumables), By End User (Hospital, Specialty Clinics, Diagnostic Centers, and Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Aug 2021
CMI4606
188 Pages
Excel & Pdf
Clinical Diagnostic

Summary

Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. Preeclampsia is a kind of high blood pressure that occur in some women after the 20th week of pregnancy or after giving birth. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. It may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death if it is not diagnosed at an early stage.

The Global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028).

Figure 1.Global Preeclampsia Diagnostics Market Share (%) in Terms of Value, By Product Type 2021

Increasing prevalence of preeclampsia is expected to drive the market growth during the forecast period.

Increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in the developed and developing nations.

Preeclampsia Diagnostics Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,270.1 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	11.8%	2028 Value Projection:	US$ $ 2,780.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Test Type: Blood Tests, Urine Analysis, Others By Product Type: Instruments, Consumables By End User: Hospital, Specialty Clinics, Diagnostic Centers, Others
Companies covered:	Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
Growth Drivers:	Increasing prevalence of preeclampsia Increasing launches of new product Increasing research and development for new tests to detect biomarkers indicating preeclampsia
Restraints & Challenges:	Lack of awareness about the preeclampsia disease

Figure 2.Global Preeclampsia Diagnostics Market Share (%), By Test Type, 2021

Increasing product launches for preeclampsia expected to drive the market growth during the forecast period

Increasing launches of new product by key players is expected to boost the market growth during the forecast period. For instance, in February 2019, Diabetomics, is a global commercial stage medical diagnostics company announced the launch of Lumella, a rapid point-of-care test for Preeclampsia in Hyderabad, India.

Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global preeclampsia diagnostics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Preeclampsia Diagnostics Market: Restraint

The major factors that hinder the growth of the global preeclampsia diagnostics market include lack of awareness about the preeclampsia disease. According to a survey conducted by Progenity, Inc. in May 2021, for cause of maternal death reveals pregnant women lack awareness about preeclampsia. Nearly 30% of pregnant women in the United States experience signs and symptoms of possible preeclampsia. Approximately 5-8% of all pregnancies are complicated by preeclampsia.

Key Players

Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

Table of Content

*Browse 27 market data tables and 31 figures on "Global Preeclampsia Diagnostics Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global preeclampsia diagnostics market size is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8 % between 2021 and 2028.

What are the major factors driving the market growth?

Factors such as increasing prevalence of preeclampsia, increasing launches of new products, and increasing research and development activities for new tests to detect biomarkers indicating preeclampsia are expected to drive the growth of the market during forecast period.

Which is the leading test type segment in the market?

Blood Tests segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factor hampering the growth of the market includes lack of awareness about the preeclampsia disease.

Which are the major players operating in the market?

Major players operating in the market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.